Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis

Abstract

Inconsistency between reported findings on the association of prostate specific antigen (PSA) gene -158G/A polymorphism with benign prostatic hyperplasia (BPH) susceptibility need a meta-analysis to obtain a more accurate conclusion. A systematic search was conducted in electronic databases for the collection of eligible studies on PSA -158G/A polymorphism and BPH susceptibility. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were then calculated. 7 case-control studies with 758 cases and 752 controls were included into the present meta-analysis. The analysis results showed no significant relationship between PSA -158G/A polymorphism and BPH susceptibility in total analysis. Interestingly, after subgroup analyses based on ethnicity and source of control, the polymorphism reduced the susceptibility of BPH in Caucasian group (AA vs. GG: OR=0.47, 95% CI=0.25-0.89; allele A vs. allele G: OR=0.68, 95% CI=0.49-0.93), but it increased the disease susceptibility in Asian (AA vs. GG: OR=1.63, 95% CI=1.02-2.60; allele A vs. allele G: OR=1.37, 95% CI=1.03-1.83) and population-based (AA vs. GG: OR=2.39, 95% CI=1.07-5.38; allele A vs. allele G: OR=1.83, 95% CI=1.26-2.65) groups. PSA-158G/A polymorphism may be an inhibitor to the incidence of BPH in Caucasians, but it is likely to be a susceptible factor in Asians.

Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients

“…Although BPH is considered to be associated with sex steroid hormone levels and has a genetic predisposition (Fang et al, 2017; Oelke et al, 2013; Su, Zeng, Fang, Liu, & Wang, 2017; Zeng et al, 2014), its exact etiology and pathogenesis remain unclear. Clinical characteristics of prostate in BPH cases can be determined by prostate volume (PV), International Prostate Symptom Score (IPSS), and maximum urinary flow rate ( Q max ).…”

Role of CYP17 rs743572 Polymorphism in Benign Prostatic Hyperplasia: A Multivariate Integrated Analysis

“…More researchers have suggested that genetic polymorphisms may play a vital role in the development of BPH (Na et al, 2017; Peng et al, 2017; Su et al, 2017; Zeng et al, 2017). Steroidal hormones (especially androgen and estrogen) play vital roles in the physiological growth and development of the prostate gland.…”

The BPSC: A prospective study investigating the clinical effect of interventional therapy and the risk factors for bladder cancer and benign prostatic hyperplasia in Chinese population

“…20 Relevant researches indicate that one in three men aged over 80 years needs treatment to relieve BPH-induced symptoms. 18,19,21,22 Apart from age, multiple factors play certain roles in the occurrence and development of BPH including sex steroid hormone levels and genetic predisposition, [23][24][25][26][27] obesity, free prostate specific antigen (PSA) level, cardiovascular disease (CVD), the use of -blocker medications, 28,29 type 2 diabetes mellitus (DM), 30 and hypertension. 31 Moreover, BPH is also considered as a component of the metabolic syndrome (Mets).…”